SEC Info - Cosmos Health Inc. - ‘8-K’ for 1/10/23

SEC Info℠

Home

Help

Please Sign In

Cosmos Health Inc. – ‘8-K’ for 1/10/23

On: Thursday, 1/12/23, at 12:20pm ET · For: 1/10/23 · Accession #: 1477932-23-211 · File #: 1-41308

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/12/23  Cosmos Health Inc.                8-K:9       1/10/23   13:152K                                   Discount Edgar/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     24K 
 2: EX-99.1     Press Release                                       HTML     13K 
 8: R1          Cover                                               HTML     46K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 9: XML         XBRL Instance -- cosm_8k_htm                         XML     15K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 5: EX-101.CAL  XBRL Calculations -- cosm-20230110_cal               XML      8K 
 7: EX-101.DEF  XBRL Definitions -- cosm-20230110_def                XML     11K 
 4: EX-101.LAB  XBRL Labels -- cosm-20230110_lab                     XML     43K 
 6: EX-101.PRE  XBRL Presentations -- cosm-20230110_pre              XML     29K 
 3: EX-101.SCH  XBRL Schema -- cosm-20230110                         XSD     19K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
13: ZIP         XBRL Zipped Folder -- 0001477932-23-000211-xbrl      Zip     17K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX:

wordproof.doc

i 0001474167 i false00014741672023-01-102023-01-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) i January 10, 2023

i Cosmos Health Inc.

(Exact name of registrant as specified in its charter)

i Nevada

i 000-54436

i 27-0611758

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

i 141 West Jackson Blvd, Suite 4236,

i Chicago, i Illinois

i 60604

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code ( i 312) i 865-0026

Cosmos Holdings Inc.

(Former name or former address, if changed since last report.)

Title of Each Class

Trading

Symbol

Name of Each Exchange

On Which Registered

i Common Stock, $.001 par value

i COSM

i Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

A copy of the Cosmos Health Inc. press release dated January 10, 2023, titled “Cosmos Health Extends and Updates its Agreement to Acquire Cana Laboratories, a European Pharmaceutical Company,” is furnished as Exhibit 99.1 to this Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Number		Description

99.1		Press Release dated January 10, 2023, titled “Cosmos Health Extends and Updates its Agreement to Acquire Cana Laboratories, a European Pharmaceutical Company.”

104		Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	COSMOS HEALTH INC.

Date: January 12, 2023	By:	/s/ *George Terzis*
		George Terzis
		Chief Financial Officer

Dates Referenced Herein

This ‘8-K’ Filing	Date	Other Filings

Filed on:	1/12/23	None on these Dates
For Period end:	1/10/23
		List all Filings

6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Cosmos Health Inc.                424B3                  1:333K                                   Discount Edgar/FA
 2/15/24  Cosmos Health Inc.                424B3                  1:163K                                   Discount Edgar/FA
 1/29/24  Cosmos Health Inc.                S-3                    4:460K                                   Discount Edgar/FA
 8/31/23  Cosmos Health Inc.                424B3                  1:185K                                   Discount Edgar/FA
 8/18/23  Cosmos Health Inc.                S-3                    4:521K                                   Discount Edgar/FA
 1/18/23  Cosmos Health Inc.                S-3                    4:530K                                   Discount Edgar/FA

↑Top

Filing Submission 0001477932-23-000211 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)